You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Patent: RE36755


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: RE36755
Title: DNA encoding tumor necrosis factor-.alpha. and -.beta. receptors
Abstract:Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
Inventor(s): Smith; Craig A. (Seattle, WA), Goodwin; Raymond G. (Seattle, WA), Beckmann; M. Patricia (Poulsbo, WA)
Assignee: Immunex Corporation (Seattle, WA)
Application Number:09/144,502
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent RE36755

Introduction

Patent RE36755, like any other patent, is subject to a stringent set of criteria and legal frameworks that define its validity, scope, and enforcement. This analysis will delve into the key aspects of patent claims, the determination of inventorship, and the broader patent landscape, using relevant examples and legal precedents.

Understanding Patent Claims

Patent claims are the heart of any patent application, as they define the scope of the invention and what is protected by the patent. The claims must be clear, concise, and fully supported by the patent specification[1].

Claim Construction

The process of interpreting patent claims is crucial for determining their validity and enforceability. Claim construction involves identifying the scope and meaning of the claims, which is essential for inventorship determination and infringement analysis. For example, in the case of Electric Power Group, LLC v. Alstom S.A., the court scrutinized the claim elements to determine if they went beyond abstract ideas and were eligible for patenting under § 101 of the U.S. patent law[2].

Abstract Ideas and Patent Eligibility

Patent claims must not be directed to abstract ideas, laws of nature, or natural phenomena without an inventive concept. The Alice analysis, as applied in Electric Power Group, LLC v. Alstom S.A., emphasizes that claims must include an inventive concept beyond merely collecting, analyzing, and displaying information in a conventional manner[2].

Determination of Inventorship

Inventorship is a critical aspect of patent law, as it determines who has the right to a patent.

Conception and Reduction to Practice

Inventorship is primarily based on the conception of the invention, which is defined as the formation in the mind of the inventor of a definite and permanent idea of the complete and operative invention. This conception must be sufficient to allow one with ordinary skill in the field to reduce the invention to practice without undue experimentation[1].

Collaborative Efforts

Inventorship can involve multiple individuals who collaborate to produce the invention. However, merely reducing an invention to practice or performing experiments does not qualify someone as an inventor unless their contributions were significant in making the invention novel or non-obvious[1].

Case Examples

In Hess v. Advanced Cardiovascular Systems, an engineer who suggested materials and explained their properties was not considered an inventor because his contributions were based on well-known principles and did not add anything novel to the invention[1].

Correction of Errors in Inventorship

Errors in naming the correct inventors can be corrected, but deceptive intent can render the patent invalid and unenforceable. For instance, in Frank’s Casing Crew v. PMR Technologies, the court found that a patent was unenforceable due to the deceptive intent of those who applied for the patent and concealed the true inventor[1].

Patent Landscape and Competitive Intelligence

Understanding the patent landscape is essential for businesses to navigate the complex world of intellectual property.

Patent File Wrappers

Reviewing patent file wrappers can provide valuable insights into the patent application process and the arguments made by examiners. This can be crucial for competitive intelligence and technology landscape analysis[4].

Patent Application Volume and Complexity

The sheer volume of patent applications, such as the 4 million processed by Serco for the U.S. Patent and Trademark Office, underscores the complexity and competitiveness of the patent landscape. Each application involves analyzing numerous claims, which highlights the meticulous nature of patent examination[5].

Standard Essential Patents (SEPs) and FRAND Licensing

SEPs are critical in standard-setting organizations and are subject to Fair, Reasonable, and Non-Discriminatory (FRAND) licensing terms.

Criticisms of the EC Proposal

The European Commission's proposal for SEP regulation has faced criticism for its non-binding FRAND determination process, which can lead to delays and unfair advantages for implementers. This proposal also overlooks the fundamental rights of patentees and the true value of SEPs, potentially undermining the incentive structure of the patent system[3].

Legal and Economic Implications

The proposed SEP regulation raises questions about the legal basis and economic consequences. It is argued that the Commission's approach deviates from well-established FRAND assessments and introduces an oversimplified top-down approach that may not accurately reflect the value of SEPs[3].

Key Takeaways

  • Clear and Specific Claims: Patent claims must be clear, concise, and fully supported by the patent specification to ensure validity and enforceability.
  • Inventorship Determination: Inventorship focuses on the conception of the invention, and errors in naming inventors can have significant legal consequences.
  • Patent Landscape Analysis: Understanding the patent landscape through tools like patent file wrappers is crucial for competitive intelligence and navigating intellectual property complexities.
  • SEP Regulation: The regulation of SEPs must balance the rights of patentees with the needs of implementers, ensuring that the incentive structure of the patent system is maintained.

FAQs

What is the significance of claim construction in patent law?

Claim construction is essential for determining the scope and meaning of patent claims, which affects the validity, enforceability, and infringement analysis of the patent.

How is inventorship determined in U.S. patent law?

Inventorship is determined based on the conception of the invention, which involves the formation of a definite and permanent idea of the complete and operative invention in the mind of the inventor.

What are the implications of the EC proposal for SEP regulation?

The EC proposal for SEP regulation has been criticized for its potential to delay dispute resolution, unfairly benefit implementers, and undermine the true value of SEPs, which could have adverse economic consequences.

Why is reviewing patent file wrappers important?

Reviewing patent file wrappers provides valuable insights into the patent application process, arguments made by examiners, and can be crucial for competitive intelligence and technology landscape analysis.

What are the consequences of deceptive intent in naming inventors?

Deceptive intent in naming inventors can render the patent invalid and unenforceable, even if the correct inventorship can be established later.

Sources

  1. Determining Inventorship for US Patent Applications - Oregon State University
  2. Electric Power Group, LLC v. Alstom S.A. - U.S. Court of Appeals for the Federal Circuit
  3. A Critical Analysis of the EC Proposal for SEP Regulation - Kluwer Patent Blog
  4. Patent file wrappers as a tool for competitive intelligence - IP Checkups
  5. Serco Processes 4 Millionth Patent Application for U.S. Patent and Trademark Office - Serco

More… ↓

⤷  Subscribe

Details for Patent RE36755

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Immunex Corporation ENBREL etanercept For Injection 103795 November 02, 1998 ⤷  Subscribe 2009-09-05
Immunex Corporation ENBREL etanercept For Injection 103795 May 27, 1999 ⤷  Subscribe 2009-09-05
Immunex Corporation ENBREL etanercept Injection 103795 September 27, 2004 ⤷  Subscribe 2009-09-05
Immunex Corporation ENBREL etanercept Injection 103795 February 01, 2007 ⤷  Subscribe 2009-09-05
Immunex Corporation ENBREL MINI etanercept Injection 103795 September 14, 2017 ⤷  Subscribe 2009-09-05
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.